Wednesday, September 14, 2011
ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, said ViroPharma started a Phase II study of a subcutaneous administration of Cinryze (C1 esterase inhibitor), in combination with Halozyme's Enhanze technology, in subjects with hereditary angioedema.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.